The stock of Aurobindo Pharma was trading at Rs 130, up 2.4 per cent after the company informed the exchanges that it had won US Food & Drug Administration (USFDA) final approval to manufacture and market Gabapentin tablets USP 600 mg and 800 mg.
Gabapentin tablets are the generic equivalent of Pfizer Pharmaceuticals’ Neurontin® tablets, which are indicated for the treatment of partial seizures and other nervous system disorders.
The annual sales of Gabapentin tablets USP 600 mg and 800 mg in the US were approximately $220 million for the 12 months ended June 2011, according to IMS and will be launched soon.
Aurobindo Pharma now has a total of 139 ANDA approvals (110 final approvals and 29 tentative approvals) from USFDA.
The total traded quantity was 1.21 lakh shares compared to the two-week average of 1.37 lakh.